Articles tagged with Colorectal Cancer
Researchers developed an exosome-based therapeutic strategy to target and treat late-stage colorectal cancer by disrupting immunosuppressive factors. In preclinical models, this approach proved effective in enhancing the anti-tumor immune response and controlling tumor growth.
Researchers developed a topical cream using BRAF inhibitor LUT014 to reduce skin rash caused by EGFR inhibitors in colorectal cancer patients. The study showed that the treatment improved skin condition and reduced severity of the rash in 6 out of 10 patients.
A new study has identified interleukin 11 as a key player in the development of colorectal cancer. IL-11-producing cells, known as cancer-associated fibroblasts, were found to promote tumor growth and support the disease microenvironment.
In a survey of 1,062 adults aged 45-75, most preferred fecal immunochemical tests (FIT/FOBT) or multitarget stool DNA (mt-sDNA) over colonoscopy. The preference for mt-sDNA was higher among younger age groups and non-Hispanic white individuals, while older adults and minority groups preferred colonoscopy.
A Mayo Clinic study found that 15.5% of patients with colorectal cancer had inherited gene mutations, which can be detected through universal testing and broader gene panels. This discovery has the potential to lead to targeted cancer therapies and earlier disease detection in families.
A modeling study estimates COVID-19-related changes in colorectal cancer screenings and associated outcomes. Expanded fecal immunochemical testing may help mitigate these outcomes during the pandemic.
Researchers found that patients with colorectal cancer had a 57-93% decreased risk of death from their cancer depending on the presence and type of mitochondrial DNA mutations. Mitochondrial DNA mutations were present in almost 60% of tumour samples, suggesting potential for improved treatment outcomes.
Regular use of baby aspirin before a diagnosis of non-metastatic colorectal cancer is associated with better survival outcomes. The study found that low-dose aspirin use limits the spread of cancerous tumors pre-diagnosis, leading to lower death rates from the disease.
A long-term study published in PLOS ONE found that bariatric surgery does not increase the risk of colorectal cancer in obese individuals. After a median follow-up period of 22 years, there were 57 cases of colorectal cancer in the surgery group and 67 in the control group, suggesting no association between the two.
A large study found a strong association between ultra-processed food consumption and an increased risk of colorectal cancer, with a 10% increment in consumption leading to an 11% increase in risk. Ultra-processed foods were also linked to less healthy diets among breast cancer cases, while no association was found with prostate cancer.
Researchers at Pennington Biomedical Research Center found that maintaining a stable body weight does not guarantee muscle mass and increases the risk of premature death among colorectal cancer survivors. Women are particularly vulnerable to losing muscle mass, with one in five women experiencing significant changes.
Scientists detected novel pathogens in colorectal cancer patients near tumors, triggering chronic inflammation that promotes cancer development. BMMFs were more frequently found near malignant tumors than healthy tissue.
A retrospective study found that folinic acid with fluorouracil improves progression-free and overall survival in metastatic colorectal cancer patients. The combination also shows a clear clinical benefit regardless of RAS mutational status or tumor side. This suggests folinic acid may be a valuable addition to chemotherapy protocols.
A new study published in the American Journal of Roentgenology found that CT colonography with a 10 mm threshold is the most effective and efficient non-invasive screening test for colorectal cancer prevention and detection. This method targets advanced neoplasia while reducing unnecessary colonoscopies compared to other tests.
A machine learning algorithm helps differentiate between benign and premalignant polyps in CT colonography data, with a sensitivity of 82% and specificity of 85%. The findings suggest a role for machine learning-derived algorithms in boosting the effectiveness of CT colonography as a screening tool for colorectal cancer.
Researchers have successfully 'caught' colibactin, a genotoxin from E. coli, inducing genetic changes characteristic of colorectal cancer cells. This breakthrough enables the observation of transformation in vitro using human colon organoids.
A new study published in JAMA Network Open examined the association between diet and colorectal cancer risk. The research found that a diet high in processed foods and added sugars is linked to an increased risk of colorectal cancer.
A new study shows that liquid biopsies can detect lingering disease in patients with oligometastatic colorectal cancer, guiding treatment decisions. The biopsies identify patients who may benefit from immune therapies or targeted treatments based on mutations detected in blood samples.
Researchers found that walnut extracts may create protective proteins and anti-inflammatory actions in the gut to safeguard against H. pylori infection and resulting cancer. The study suggests a promising non-bacterial approach to reduce symptoms of H. pylori infection, warranting further clinical trial investigation.
Researchers sent take-at-home tests to patients overdue for screenings, increasing completion rates by nearly 20% compared to traditional reminders. The intervention cost just $150 per patient, a critical factor for sustainability in community health centers.
A study of over 200,000 veterans found that delays in colonoscopy after an abnormal stool blood test increase the risk of colorectal cancer and death. Colonoscopy within one year of an abnormal stool test is recommended to prevent polyp progression and stage migration of colorectal cancer.
A new study found that delaying colonoscopies after abnormal at-home screenings by over 12 months increases the risk of colorectal cancer diagnosis and death. The odds of being diagnosed with late-stage colon cancer increased by approximately 33% at 16 months.
A new study suggests that long-term aspirin use before a diagnosis of colorectal cancer may be associated with lower CRC-specific mortality. Preventing distant metastases leads to fewer deaths from colorectal cancer.
Researchers at Nagoya University have discovered two types of fibroblasts, meflin and gremlin 1, that play a crucial role in regulating colorectal cancer progression. Altering the balance between these cells could be an effective strategy for preventing cancer progression.
A new technique using deep mutational scanning has identified important mutations in the MSH2 gene associated with Lynch Syndrome, a major cause of hereditary non-polyposis colorectal cancer. This approach could improve predictive value of genetic screening for individuals at risk of developing colorectal cancer.
Research found cancer patients in low-income countries are up to four times more likely to die following surgery, with less post-operative care infrastructure and oncology services. Patients from upper middle-income countries were two times as likely to die compared to high-income countries.
The global demand for cancer surgery is projected to increase by 52% between 2018 and 2040, with the largest relative increase in low-income countries. Improving care systems worldwide is crucial to reduce mortality rates from complications.
African-Americans are more likely to develop cancerous lesions on the right side and suffer from colorectal cancer at a younger age due to unique biological aging patterns. The research found that the right side of the colon in most African-Americans had suffered epigenetic changes contributing to their increased cancer risk.
A recent study found that daily aspirin use does not reduce the risk of colorectal cancer among adults who start taking it after age 70. However, there may be a potential benefit for those who begin taking aspirin at an earlier age.
Researchers developed a simple, affordable test to detect hidden blood in feces, helping identify those at risk of developing colorectal cancer. The test has shown exceptional performance in detecting the disease in patients with low-risk symptoms, reducing the need for unnecessary colonoscopies.
A triple drug combination of irinotecan, cetuximab, and vemurafenib has shown better tumor response rates and longer cancer-free periods compared to a two-drug combination in patients with metastatic colorectal cancer. The treatment targets the BRAF protein directly and blocks cancer growth by targeting epidermal growth factor receptor.
The Stand Up To Cancer initiative will fund a 'Dream Team' of researchers and public awareness campaigns to increase screenings in medically underserved communities. The goal is to develop better approaches to colorectal cancer interception and make the disease preventable with simple tests, while addressing health disparities.
The FDA has approved pembrolizumab, a new immunotherapy drug, as the first-line treatment for patients with advanced colorectal cancer. This approval was made possible by early results from a phase III clinical trial funded by Stand Up To Cancer (SU2C) research.
A new study found that higher BMI is more dangerous for men than women, while a higher waist-to-hip ratio raises colorectal cancer risk in women. Maintaining a healthy weight can reduce the risk of this deadly cancer.
Researchers analyzed SEER 18 data and found adenocarcinomas to be the predominant cancer subtype in screening, surveillance, and prevention. The study also revealed that carcinoid tumors are increasing at a faster rate than adenocarcinomas, but adenocarcinomas are still steadily increasing in most early-onset subgroups.
Researchers discovered that a high proportion of advanced carcinomas carry a mutant form of the Siglec-XII protein, which is rarely expressed in normal humans. This finding may explain why humans are more prone to aggressive cancers compared to chimpanzees.
Residents of Southwest Virginia have set priorities for cancer prevention and early detection, focusing on tobacco cessation, HPV vaccination, lung and colorectal cancer screenings. The region's partnership with the UVA Cancer Center Without Walls aims to improve health outcomes through a collaborative effort.
A new study published in Neurology found that people with multiple sclerosis (MS) had a 72% greater risk of developing bladder cancer compared to those without the disease. However, breast and colorectal cancers did not show a significant association with MS.
A new study published in the Journal of the American College of Surgeons suggests that Medicaid expansion under the Affordable Care Act may lead to earlier diagnoses of colon cancer. Researchers found improved access to care and enhanced surgical care for patients with colon cancer in states that implemented Medicaid expansion.
Researchers have identified specific geographic areas in the US where women diagnosed with early-onset colorectal cancer before age 50 face higher mortality rates. The study found nearly one quarter of adults in hot spot counties reported no physical activity, and fertility may contribute to this variation.
A new predictive model estimates personal risk for advanced polyps and colon cancer in average risk individuals, helping physicians determine screening options. The study identifies lower and higher risk groups among average risk individuals, with approximately 10% deemed high risk for a colonoscopy.
Researchers found that higher-quality diets were associated with improved overall survival among individuals with metastatic colorectal cancer. The study, published in JAMA Network Open, suggests that dietary interventions may be a crucial component of cancer treatment and management.
Researchers at ChristianaCare's Helen F. Graham Cancer Center & Research Institute have identified a link between two crucial signaling pathways in the development and growth of colon cancer. The study found that an imbalance between WNT and RA signaling can lead to the evolution of colorectal cancer from stem cell populations.
The KRYSTAL-1 phase I/II clinical trial has shown that adagrasib can shrink tumours and is well-tolerated by patients with non-small cell lung cancer, colorectal cancer, and other solid tumours. The KRAS G12C mutation affects approximately 14% of lung adenocarcinomas and 4% of colorectal cancers.
Adagrasib achieves objective responses in nearly half of patients with non-small cell lung cancer; encouraging early results are seen in patients with colorectal, pancreatic, and endometrial cancer. The agent targets KRAS G12C mutation, leading to manageable side effects.
A new study found that a faecal immunochemical test (FIT) is almost 100% accurate at ruling out bowel cancer in patients with suspicious symptoms. FIT has been shown to be as sensitive as colonoscopy, the current gold standard for detection of colorectal cancer.
Research reveals thymoquinone's ability to induce apoptosis and DNA damage in 5-Fluorouracil-resistant colorectal cancer, demonstrating its potential as a therapeutic agent. The compound targets CSCs enriched from both sensitive and resistant cell lines, suggesting a promising effect on chemoresistant cells.
The new guideline provides options for different treatments to improve survival rates and quality of life for patients with locally advanced rectal cancer. Recommendations address patient selection, pelvic radiation treatments, integration with chemotherapy and surgery, and follow-up care.
A study of over 600 patients with colorectal cancer found that higher levels of T cells and greater diversity of T cell receptors are associated with better outcomes. The new biomarker, called TCR immuno-sequencing, measures the amount of infiltrated T lymphocytes and their clonality.
Researchers at Sanford Burnham Prebys Medical Discovery Institute have discovered a way to selectively kill aggressive cancer cells by blocking the construction of nuclear pore complexes. This breakthrough could lead to new treatments for deadly tumors such as melanoma, leukemia, and colorectal cancer.
Kanneganti's research focuses on the innate immune system, inflammation, and cell death in health and disease, particularly in colorectal cancer. She aims to understand how innate immune pathways contribute to tumor development and improve cancer treatment strategies.
Researchers discovered that R-spondin treatment reduces intestinal tumor growth and promotes healthy epithelial cell function. The study suggests a new rationale for treating familial adenomatous polyposis patients with APC mutations.
A national survey found that many cancer patients lack nutritional advice and face difficulties such as diarrhoea, appetite loss, and changes in taste and smell. Researchers emphasize the importance of individualized guidance for improved quality of life and overall survival.
A phase 1 clinical trial of sotorasib (AMG 510) demonstrated anti-cancer activity in patients with heavily pretreated advanced solid tumors. Patients with non-small cell lung cancer had a 32% response rate and median progression-free survival of 6.3 months.
A large observational study found that patients who drank two to three cups of coffee per day had longer survival and a lower risk of cancer worsening compared to those who didn't drink coffee. The benefits held for both caffeinated and decaffeinated coffee, but further research is needed to determine the causal connection.
Researchers found that moderate coffee drinkers had a lower risk of death from colorectal cancer compared to non-coffee drinkers. The study suggests that coffee's antioxidant properties may contribute to its potential health benefits for patients with the disease.
A team of scientists has unraveled the molecular basis underlying colorectal cancer by discovering how mutations in RNF43 activate the Wnt signaling pathway. This finding provides potential treatment options for certain types of colorectal cancer.
A study by Florida Atlantic University found that 28.6% of high-risk patients were unaware of the need for repeat colonoscopy or the proper surveillance interval. The researchers emphasize the importance of objective data and clinician sharing findings to improve patient care.
A new study by City of Hope researchers found that Black patients are less likely to receive chemotherapy and have a higher chance of death compared to white patients with advanced colorectal cancer. The study suggests that all patients with liver metastases should be evaluated for surgery, regardless of race.
A new hybrid signature based on DNA mutation and RNA expression patterns has been developed to predict the mutation status and survival of colorectal cancer (CRC) patients. The model achieved high accuracy and was found to be prognostic for CRC patients.